China Drug Administration publishes a key Draft Guidance on data exclusivity for pharmaceuticals

This is the first time the China Drug Administration (CDA) provides details on how the data exclusivity applies to pre-clinical and clinical data submitted to the agency. Companies with plans to launch pharmaceutical products in China should carefully review the Draft Guidance and assess its implications.

Read more: China Drug Administration publishes a key Draft Guidance on data exclusivity for pharmaceuticals 


Download PDF Share Back To Listing
Loading data